文献速递临床试验与 GCP

羟氯喹治疗轻度Graves眼病(GO-HCQ)的随机对照试验:研究方案

A randomized controlled trial on the effect of hydroxychloroquine in mild Graves' orbitopathy (GO-HCQ): study protocol.
PubMed 文献 · Trials · 2025-08-04

本研究为在台湾开展的多中心开放标签随机对照试验,计划纳入108例轻度Graves眼病患者,按2:1随机分配至羟氯喹组和对照组,主要终点为包括睑裂宽度、软组织受累和眼球突出的复合眼科指标,次要终点包括生活质量、眼眶CT体积测量、复视评分、临床活动度评分、视力和甲状腺自身抗体。

要点

  • 多中心开放标签随机对照试验,纳入108例轻度Graves眼病患者,羟氯喹组与对照组按2:1随机分配。
  • 主要终点为睑裂宽度、软组织受累和眼球突出的复合眼科指标。
  • 次要终点包括生活质量(GO-QoL)、眼眶CT体积测量、复视评分、临床活动度评分、视力和甲状腺自身抗体。

核心结论

  • 本随机对照试验将阐明口服羟氯喹对轻度Graves眼病患者的临床获益,评估眼科结局、生活质量、疾病活动度和甲状腺自身抗体。

研究设计与样本

  • 在台湾开展的多中心开放标签随机对照试验,共108例参与者随机分为羟氯喹组和对照组,分配比为2:1。

主要发现

  • 眼眶CT测量数据将为了解眼眶脂肪和眼外肌体积的细微变化提供有价值的信息,可能为监测Graves眼病进展提供客观工具。

关键数值与推荐

  • 主要终点为包括睑裂宽度、软组织受累和眼球突出的复合眼科指标。
  • 次要终点包括生活质量(GO-QoL)变化、通过计算机断层扫描(CT)进行的眼眶体积测量、复视评分、临床活动度评分(CAS)、视力和甲状腺自身抗体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Graves' orbitopathy (GO) is a prevalent manifestation of Graves' disease (GD), characterized by proptosis, eyelid retraction, soft tissue swelling, diplopia, and potential visual acuity impairment. Furthermore, even mild GO can significantly impact mental health and overall quality of life for patients with GD. Despite its severity, available medical treatments for mild GO are limited. Recent basic studies on orbital fibroblasts suggest hydroxychloroquine (HCQ) as a promising therapeutic agent for GO patients. This randomized controlled trial (RCT) was designed to assess the efficacy of HCQ in treating mild GO. METHODS: This multi-center open-label RCT will be conducted in Taiwan with a total of 108 participants randomized into HCQ and control groups at 2:1 allocation ratio. The primary endpoint of this study is a composite outcome of ophthalmic parameters including eyelid aperture, soft tissue involvement, and exophthalmos. Secondary endpoints comprise changes in quality of life (GO-QoL), orbital volumetry via computed tomography (CT), diplopia scores, clinical activity scores (CAS), visual acuity, and thyroid autoantibodies. DISCUSSION: This RCT will elucidate the clinical benefits of oral HCQ in patients with mild GO, assessing ophthalmic outcomes, quality of life, disease activity, and thyroid autoantibodies. In addition, data obtained from orbital CT measurements will provide valuable insights into subtle changes in orbital fat and extra-ocular muscle volumes, potentially offering an objective tool for monitoring GO progression. TRIAL REGISTRATION {2A, 2B}: ClinicalTrials.gov NCT05126147. Registered on November 2021. https://clinicaltrials.gov/study/NCT05126147 . All items from the World Health Organization (WHO) Trial Registration Data Set are addressed within the relevant sections of this protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lin CH, Wei YH, Lu JY, et al. A randomized controlled trial on the effect of hydroxychloroquine in mild Graves' orbitopathy (GO-HCQ): study protocol. Trials. 2025. PMID: 40760017. doi:10.1186/s13063-025-09002-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。